Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We discuss why silica nanoparticles, such as Nuvec®, are one of the most promising siRNA delivery systems available in pre-clinical research for oral drug administration.
Read the article published in ONdrugDelivery here.
